Saturday, December 10, 2016

Aurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area.

   
News Releases
Aurinia Highlights Renal Function at ASN Kidney Week
November 21, 2016 read more ...

Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in LN
November 16, 2016 read more ...

Aurinia to Present at Stifel 2016 Healthcare Conference
November 10, 2016 read more ...

Aurinia Establishes At-the-Market Facility
November 9, 2016 read more ...

Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights
November 4, 2016 read more ...

Aurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of LN..
November 2, 2016 read more ...

Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation...
October 24, 2016 read more ...

Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates...
October 6, 2016 read more ...

Aurinia Announces that Voclosporin Achieves Primary and all Pre-Specified Secondary Endpoints
September 29, 2016 read more ...

Aurinia Announces Voclosporin Meets Primary Endpoint
August 15, 2016 read more ...

View more news releases
Click here read more ...

 

Lupus Nephritis – Our Core Strategic Focus

Our lead drug, voclosporin, is an immunosuppressant that has utility across many indications. Although voclosporin has been shown to be effective in indications such as prevention of rejection in renal transplantation, it is the lupus market where our company’s key focus now lies.  Kidney Inflammation caused by Systemic Lupus Erythematosus (SLE) is referred to as lupus nephritis (LN), and it is estimated that approximately 40-50% of all SLE patients have clinical LN requiring treatment. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (eGFR), and increased serum creatinine levels.  Poorly controlled LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially life-threatening condition.

 

  Voclosporin 






Media Coverage
View more media
Click here read more ...

Home   |   About Aurinia   |   Our Team   |   Products In Development   |   For Investors   |   Partnerships   |   Contact
Copyright 2013 by Aurinia Pharmaceuticals Inc.